- Patent Title: Fusion protein comprising a blood-brain barrier (BBB)-crossing single domain antibody Fc5, an immunoglobulin Fc fragment and a beta-amyloid binding polypeptide (ABP)
-
Application No.: US16481898Application Date: 2018-01-30
-
Publication No.: US11702466B2Publication Date: 2023-07-18
- Inventor: Balu Chakravarthy , Danica Stanimirovic , Yves Durocher
- Applicant: National Research Council of Canada
- Applicant Address: CA Ottawa
- Assignee: National Research Council of Canada
- Current Assignee: National Research Council of Canada
- Current Assignee Address: CA Ottawa
- Agency: Cooley LLP
- International Application: PCT/IB2018/050576 2018.01.30
- International Announcement: WO2018/138709A 2018.08.02
- Date entered country: 2019-07-30
- Main IPC: C07K16/46
- IPC: C07K16/46 ; C07K16/00 ; C07K14/00 ; A61K39/00 ; A61K38/00 ; C07K16/18 ; A61K9/00 ; C07K14/47
Abstract:
A brain-penetrating composition of amyloid-ß binding peptide is disclosed. This may be useful in the treatment of Alzheimer's disease, for example as a bifunctional molecule, comprising a blood-brain barrier crossing antibody and an amyloid-ß targeting peptide linked via an Fc fragment that is able to transmigrate across the blood-brain barrier into the brain, and compositions comprising same. Methods of using this composition for treating Alzheimer's disease are disclosed.
Public/Granted literature
- US20190352383A1 BLOOD-BRAIN BARRIER TRANSMIGRATING COMPOUNDS AND USES THEREOF Public/Granted day:2019-11-21
Information query
